Corvus Pharmaceuticals's total assets for Q3 2024 were $58.81M, a decrease of -8.90% from the previous quarter. CRVS total liabilities were $46.41M for the fiscal quarter, a 646.44% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.